You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
Cambium Bio secures A$10.85 million to initiate the pivotal Phase 3 trial of Elate Ocular®, targeting moderate to severe dry eye disease.
PRIVATESep 16, 2026•about 3 hours ago
Amount Raised
$10.9 Million
Round Type
Venture - Series Unknown
AssamBiotechnologyHealth Care
Description
Cambium Bio Limited has secured an A$10.85 million funding package to start its pivotal Phase 3 trial of Elate Ocular® for dry eye disease. The funding includes A$7.1 million from strategic shareholders and an A$3.75 million secured facility. This funding is a significant step towards bringing the first biologic therapy for dry eye disease to market. The placement is conditional on shareholder approval at the Company's 2026 Annual General Meeting.
Company Information
Company
Cambium Bio Limited
Location
Assam, India
About
Cambium Bio Limited operates in the biotechnology sector, focusing on innovative solutions. The company is engaged in the development of products that focus on health and medical advancements. It has undergone a merger impacting its substantial holding status.
Don't miss Cambium Bio Limited's next move
Get an email the moment Cambium Bio Limited raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Cambium Bio Limited's next move
AssamBiotechnologyHealth Care